Parenteral nutrition for patients with advanced ovarian malignancy.

BACKGROUND Parenteral nutrition (PN) in patients with disseminated ovarian cancer remains controversial. The role of PN in providing nutrition and improving quality of life is unclear. The present study aimed to determine the pattern of prescribing in a large teaching hospital, and to identify subgroups where the use of PN was justified. METHODS Sixty-five patients with advanced ovarian carcinoma received PN between January 2002 and May 2008. A retrospective case note review was undertaken to retrieve data on PN prescribing and outcomes in terms of duration of PN provision, complications, and survival. RESULTS Three subgroups were identified. Group I consisted of 18 (28%) patients who received PN for a median [interquartile range (IQR)] of 5 (2-11) days. The majority of these 18 patients (n = 13, 72%) had disease-related terminal bowel obstruction. Out of 18 of these patients, 17 (95%) had poor performance status. The median (IQR) survival was 12 (6-28) days. Group II consisted of 40 (61%) patients who were re-established on enteral nutrition. The median (IQR) duration of PN administration was 10 (6-17) days. The most common indication of PN was protracted ileus (n = 25, 63%). Out of 40 of these patients, 35 (88%) patients had good performance status. The median (IQR) survival was 264 (96-564) days. The third group of patients required home PN (n = 7, 11%). Four (58%) patients had short bowel syndrome and three (42%) had terminal intestinal obstruction. All of the patients had good performance status. The median (IQR) duration of PN administration and survival was 241 (90-305) days. CONCLUSIONS Administration of PN appears to be justified in those patients with a good performance status (i.e. patients capable of self-care), which constituted three-quarters of this cohort. In the remaining patients with poor performance status, and particularly those with terminal intestinal obstruction, PN administration was difficult to justify. PN should not be denied based purely on the pathology, although cautious judgment is required to select those who are most likely to benefit.

[1]  Richard G. Moore,et al.  The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. , 2006, Gynecologic oncology.

[2]  D. Duerksen,et al.  Is there a role for TPN in terminally ill patients with bowel obstruction? , 2004, Nutrition.

[3]  G. Jayson,et al.  Doctor, does this mean I'm going to starve to death? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Bachmann,et al.  Summary version of the Standards, Options and Recommendations for palliative or terminal nutrition in adults with progressive cancer (2001) , 2003, British Journal of Cancer.

[5]  M. Meguid,et al.  Use of TPN in terminally ill cancer patients. , 1999, Nutrition.

[6]  C. Loprinzi,et al.  Should cancer patients with incurable disease receive parenteral or enteral nutritional support? , 1998, European journal of cancer.

[7]  E. Venkatraman,et al.  Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. , 1997, Gynecologic oncology.

[8]  J. Philip,et al.  The role of total parenteral nutrition for patients with irreversible bowel obstruction secondary to gynecological malignancy. , 1997, Journal of pain and symptom management.

[9]  M. Shike.  Nutrition therapy for the cancer patient. , 1996, Hematology/oncology clinics of North America.

[10]  S. Fan,et al.  Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. , 1994, The New England journal of medicine.

[11]  P. Pisters,et al.  A Prospective Randomized Trial of Total Parenteral Nutrition After Major Pancreatic Resection for Malignancy , 1994, Annals of surgery.

[12]  L. Twiggs,et al.  Outcome assessment of home parenteral nutrition in patients with gynecologic malignancies: what have we learned in a decade of experience? , 1993, Gynecologic oncology.

[13]  D. August,et al.  Home parenteral nutrition for patients with inoperable malignant bowel obstruction. , 1991, JPEN. Journal of parenteral and enteral nutrition.

[14]  R. Park,et al.  A technique for managing terminally ill ovarian carcinoma patients. , 1991, Gynecologic oncology.

[15]  R. Brand,et al.  Total parenteral nutrition and sepsis. , 1988, Archives of disease in childhood.

[16]  J. Simes,et al.  Total parenteral nutrition and cancer clinical trials , 1986, Cancer.

[17]  W. James,et al.  Basal metabolic rate : review and prediction, together with an annotated bibliography of source material , 1985 .

[18]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[19]  T. Julian,et al.  Perioperative total parenteral nutrition in patients with gastrointestinal cancer. , 1981, The Journal of surgical research.

[20]  J. Fischer,et al.  The effects of perioperative hyperalimentation on complications in patients with carcinoma and weight loss. , 1977, The Journal of surgical research.

[21]  E. Copeland,et al.  Intravenous hyperalimentation in cancer patients. , 1974, The Journal of surgical research.